[The Plasma (13)-β-D-glucan Assay, a Japanese Contribution to the Diagnosis of Invasive Fungal Infection]

Taminori Obayashi1

  • 1Medical Laboratory, Higashi Saitama General Hospital.

Medical Mycology Journal
|December 1, 2017
PubMed

Insights

The (1→3)-β-D-glucan assay aids invasive fungal infection diagnosis. However, differing kit sensitivities, particularly in Japan, may lead to missed diagnoses, necessitating global standardization for reliable results.

Area of Science:

  • Clinical diagnostics
  • Mycology
  • Biochemistry

Background:

  • The (1→3)-β-D-glucan assay, developed in Japan in 1985, utilizes horseshoe crab amebocytes to detect fungal infections.
  • It is now a globally recognized diagnostic aid for invasive fungal infections, included in international practice guidelines.
  • Two distinct commercial assay kits, colorimetric and turbidimetric, are prevalent in Japan, exhibiting significant differences in sensitivity.

Purpose of the Study:

  • To highlight the critical differences in sensitivity between colorimetric and turbidimetric (1→3)-β-D-glucan assays.
  • To address concerns regarding the potential for missed diagnoses due to assay variability.
  • To advocate for global standardization of (1→3)-β-D-glucan testing methods.

Main Methods:

  • Comparison of measurement values and sensitivity between colorimetric and turbidimetric (1→3)-β-D-glucan assay kits.
  • Analysis of detection limits and cutoff values for each assay type.
  • Review of clinical trial data and practice guideline incorporation.

Main Results:

  • A significant sensitivity disparity exists: 1 pg/ml in turbidimetric assays often equates to approximately 7 pg/ml in colorimetric assays.
  • The turbidimetric assay's higher cutoff value and detection limit (equivalent to 60 pg/ml colorimetric) raise concerns about missing low-concentration infections.
  • Variability in kit sensitivity is also observed internationally, impacting inter-assay data comparability.

Conclusions:

  • The differing sensitivities of commercial (1→3)-β-D-glucan assays, especially in Japan, pose a risk of underdiagnosing invasive fungal infections.
  • Global harmonization and standardization of these assays are crucial for accurate diagnosis and effective patient management.
  • Future developments, including genetic engineering for enzyme sources, may offer new avenues for standardization and animal welfare.

Related Concept Videos